40 likes | 271 Views
Memantine in Severe Dementia: Results of the M-Best Study Benefit and Efficacy in Severely Demented Patients During Treatment With Memantine. B. Winblad and N. Poritis International Journal of Geriatric Psychiatry 1999, 14: 135-146 . Study Design. No. of patients N = 166 (nursing home)
E N D
Memantine in Severe Dementia: Results of the M-Best StudyBenefit and Efficacy in Severely Demented Patients During Treatment With Memantine B. Winblad and N. Poritis International Journal of Geriatric Psychiatry 1999, 14: 135-146
Study Design No. of patients N = 166 (nursing home) Design Double-blind, randomized, placebo- controlled, multicenter study Diagnosis Primary dementia (AD, VaD, mixed types) Age 60 – 80 years (mean 68.4) Severity MMSE < 10 (mean 6.3), GDS 5 – 7 Dose; duration 10 mg memantine/day; 12 weeks Primary efficacy Global: CGI-C parameters Care Dependence: BGP subscore Secondary efficacy Function/Behavior: D-Scale, BGPparameter Winblad and Poritis., Int J Geriat Psychiatr 1999
80 70 60 50 40 30 20 10 0 ** 73% * 59% 45% 40% Memantine Placebo Memantine Placebo Week 4 Week 12 Memantine Improves Global Impression (CGI-C) ITT analysis, N = 166 Response = improvement Responders [%] in CGI-C *p = 0.006, ** p = 0.001 versus placebo Winblad and Poritis., Int J Geriat Psychiatr 1999
Summary • Memantine is efficacious in severely demented patients suffering from probable Alzheimer’s disease or probable vascular dementia • Functional improvement was significant in memantine- treated patients • Tolerability of memantine was good Winblad and Poritis., Int J Geriat Psychiatr 1999